Hisamitsu Pharmaceutical Co., Inc.
OTC: HTSUF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kazuhide Nakatomi
- Employees
- 2,759
- Headquarters
- Tosu, Japan
- IPO year
- 2010
- Market cap
- $2.0B
- Website
- https://www.hisamitsu.co.jp
Loading HTSUF…
Loading profile data…Frequently asked questions about HTSUF
What does Hisamitsu Pharmaceutical Co., Inc. (HTSUF) do?
Hisamitsu Pharmaceutical Co., Inc. is a Japanese enterprise that develops and markets a range of pharmaceuticals, quasi-drugs, and medical devices. Its extensive product catalog includes popular external pain relief solutions such as SALONPAS, NOBINOBI, SALONSIP, AIR, and FEITAS. The company also provides targeted treatments like BUTENALOCK for...
Where does HTSUF trade?
Hisamitsu Pharmaceutical Co., Inc. (HTSUF) trades on the Other OTC.
What sector is HTSUF in?
Hisamitsu Pharmaceutical Co., Inc. (HTSUF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Hisamitsu Pharmaceutical Co., Inc.?
Kazuhide Nakatomi is the chief executive officer of Hisamitsu Pharmaceutical Co., Inc. (HTSUF).
Where is Hisamitsu Pharmaceutical Co., Inc. headquartered?
Hisamitsu Pharmaceutical Co., Inc. is headquartered in Japan.
Does HTSUF pay a dividend?
Yes — Hisamitsu Pharmaceutical Co., Inc. (HTSUF) paid a trailing twelve-month dividend of USD 0.82 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did HTSUF go public?
Hisamitsu Pharmaceutical Co., Inc. (HTSUF) completed its initial public offering in 2010.